Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,715 | 95 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $510.33 | 25 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $435.22 | 27 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $162.25 | 9 | $0 (2021) |
| UCB, Inc. | $138.77 | 8 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $126.31 | 6 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $104.24 | 6 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $63.99 | 4 | $0 (2018) |
| CSL Behring | $62.54 | 4 | $0 (2021) |
| Amgen Inc. | $40.87 | 2 | $0 (2021) |
| iRhythm Technologies, Inc. | $27.89 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $82.41 | 4 | PFIZER INC. ($82.41) |
| 2022 | $151.29 | 7 | PFIZER INC. ($133.39) |
| 2021 | $484.40 | 23 | PFIZER INC. ($178.96) |
| 2020 | $206.43 | 12 | Janssen Pharmaceuticals, Inc ($89.00) |
| 2019 | $259.88 | 15 | PFIZER INC. ($72.04) |
| 2018 | $244.90 | 14 | Janssen Pharmaceuticals, Inc ($70.14) |
| 2017 | $285.66 | 20 | Janssen Pharmaceuticals, Inc ($122.64) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/20/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, ZAVZPRET | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/26/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/29/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/10/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/15/2022 | PFIZER INC. | ELIQUIS (Drug), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $26.22 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/19/2022 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/10/2022 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/02/2022 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/12/2022 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/19/2022 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/06/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/11/2021 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/17/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: DIABETES | ||||||
| 11/12/2021 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/03/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/21/2021 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Neurology | ||||||
| 10/06/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/22/2021 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/08/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Cardiology | ||||||
| 08/27/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/26/2021 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/11/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/15/2021 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/30/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $18.03 | General |
| Category: Cardiovascular | ||||||
| 06/16/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 746 | 1,147 | $373,791 | $103,293 |
| 2022 | 11 | 895 | 1,345 | $332,478 | $108,572 |
| 2021 | 12 | 856 | 1,312 | $317,129 | $105,821 |
| 2020 | 14 | 885 | 1,262 | $312,402 | $106,574 |
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 262 | 603 | $173,664 | $52,814 | 30.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 218 | 223 | $66,008 | $18,719 | 28.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 145 | 147 | $81,879 | $18,263 | 22.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 76 | 124 | $24,800 | $7,241 | 29.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 19 | 24 | $18,816 | $3,750 | 19.9% |
| 99316 | Nursing facility discharge management, more than 30 minutes | Facility | 2023 | 14 | 14 | $4,088 | $1,358 | 33.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $4,536 | $1,148 | 25.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 231 | 545 | $122,080 | $40,394 | 33.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 117 | 117 | $50,895 | $15,849 | 31.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 173 | 181 | $41,811 | $14,061 | 33.6% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 97 | 99 | $39,600 | $12,774 | 32.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 65 | 141 | $22,137 | $7,416 | 33.5% |
| 99226 | Follow-up observation care per day, typically 35 minutes | Facility | 2022 | 61 | 76 | $17,176 | $5,672 | 33.0% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 92 | 95 | $14,915 | $4,888 | 32.8% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 20 | 50 | $7,850 | $2,630 | 33.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 12 | 14 | $8,274 | $2,259 | 27.3% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 12 | 12 | $4,320 | $1,470 | 34.0% |
| 99316 | Nursing facility discharge management, more than 30 minutes | Facility | 2022 | 15 | 15 | $3,420 | $1,158 | 33.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 212 | 560 | $125,440 | $42,587 | 34.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 104 | 105 | $45,675 | $14,694 | 32.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 175 | 178 | $41,118 | $14,000 | 34.0% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2021 | 82 | 82 | $32,800 | $10,462 | 31.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 71 | 149 | $23,393 | $7,828 | 33.5% |
| 99226 | Subsequent observation care, typically 35 minutes per day | Facility | 2021 | 52 | 68 | $15,368 | $5,017 | 32.6% |
| 99217 | Hospital observation care on day of discharge | Facility | 2021 | 91 | 91 | $14,287 | $4,612 | 32.3% |
About Dr. Adam Macdissi, M.D
Dr. Adam Macdissi, M.D is a Internal Medicine healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2010. The National Provider Identifier (NPI) number assigned to this provider is 1720399116.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Macdissi, M.D has received a total of $1,715 in payments from pharmaceutical and medical device companies, with $82.41 received in 2023. These payments were reported across 95 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,715).
As a Medicare-enrolled provider, Macdissi has provided services to 3,382 Medicare beneficiaries, totaling 5,066 services with total Medicare billing of $424,261. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hospitalist, Hospitalist
- Location Omaha, NE
- Active Since 06/30/2010
- Last Updated 09/09/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1720399116
Products in Payments
- ELIQUIS (Drug) $607.04
- XARELTO (Drug) $435.22
- ENTRESTO (Drug) $126.31
- Vimpat (Drug) $80.60
- JARDIANCE (Drug) $69.30
- CHANTIX (Drug) $65.54
- Kcentra (Biological) $62.54
- Briviact (Drug) $58.17
- Repatha (Biological) $40.87
- STIOLTO RESPIMAT (Drug) $34.94
- ZERBAXA (Drug) $33.23
- ZIO Patch (Device) $27.89
- XIFAXAN (Drug) $25.03
- Orbactiv (Drug) $17.53
- CUBICIN RF (Drug) $16.68
- JANUMET (Drug) $14.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Omaha
Mojtaba Akhtari, M.d, M.D
Internal Medicine — Payments: $1.6M
Dr. Matthew Lunning, D.o, D.O
Internal Medicine — Payments: $650,808
Michael Dunn, M.d, M.D
Internal Medicine — Payments: $221,491
Dr. Brian Boer, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $96,162
Dr. Trevor Van Schooneveld, M.d, M.D
Internal Medicine — Payments: $91,007
Dr. Michael Schafer, Md, MD
Internal Medicine — Payments: $60,335